

# Standard Operating Procedure

	SOP CODE:	USA – STRL – P4.1.2.0	REVISION NUMBER: 2 . 0 . 0
	ISSUE DATE:	MONTH 00, YYYY	
	IMPLEMENTATION DATE:	MONTH 00, YYYY	
	<input type="checkbox"/> CONTROLLED COPY	<input type="checkbox"/> UNCONTROLLED COPY _____	

**TITLE : PROCESS – DEVELOPING – AQUEOUS SOLUTION INJECTIONS FOR HOSPITALS – COMPOUNDING PRACTICES**

Page 1 of 10

<b>DRAFTED BY:</b> <input type="text"/> n/a	<b>SIGNATORY:</b>  <b>TITLE:</b>	_____ SIGNATURE	_____ DATE
<b>VERIFIED BY:</b> <input type="text"/> n/a	<b>SIGNATORY:</b>  <b>TITLE:</b>	_____ SIGNATURE	_____ DATE
<b>APPROVED BY:</b>	<b>SIGNATORY:</b>  <b>TITLE: DESIGNATED PERSON</b>	_____ SIGNATURE	_____ DATE
<b>APPROVED BY:</b> <input type="text"/> n/a	<b>SIGNATORY:</b>  <b>TITLE: DESIGNATED PERSON</b>	_____ SIGNATURE	_____ DATE

**This SOP contains procedural steps for use against SARS-CoV-2, the novel coronavirus that causes the disease COVID-19.**

## COMPENDIAL APPLICABILITY OF THE USP GENERAL CHAPTER <800>

“On December 1, 2019, USP’s standard on the safe handling of hazardous drugs, General Chapter <800>, became official. General Chapter <800> is informational and not compendially applicable. USP General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings describes practice and quality standards for handling hazardous drugs. USP is committed to maintaining patient access to medicines, while supporting patient safety, healthcare worker safety, and environmental protection when handling HDs (hazardous drugs) in healthcare facilities.” (USP Publication: Compendial Applicability of USP 800).

Please see the document titled, compendial-applicability-of-usp-800.pdf in the folder titled, 10 – Supplemental Documentation\References and Standards for additional details.

To determine the regulatory applicability of the USP General Chapter <800>, you must contact your State Board of Pharmacy.

DISCLAIMER: Copyright© Medisca Pharmaceutique Inc. 2015-2020. Any reproduction, reprint or copy, in electronic or print version, is strictly prohibited without the expressed written consent of Medisca Pharmaceutique Inc. Medisca Network Inc takes no responsibility for the content of this document and shall not be held liable to any person or entity concerning claims, loss, or damage cause by, or alleged to be cause by, directly or indirectly, the use or misuse of the information contained in the suggested Standard Operating Procedures. Adjustments may be needed by end-user licensed pharmacist or other appropriately state licensed professional prior to use, to meet specific needs. Medisca Network Inc. shall not be liable for any adjustments made to the suggested Standard Operating Procedures. All suggested Standard Operating Procedures should be validated, approved and authorized for use by the end-user licensed pharmacist or other appropriately state licensed professional prior to use. In all cases, it is the responsibility of the licensed pharmacist or other appropriately state licensed professional to know the law and to act in accordance with federal and state law.

# Standard Operating Procedure

	SOP CODE:	USA – STRL – P4.1.2.0	REVISION NUMBER: 2 . 0 . 0
	ISSUE DATE:	MONTH 00, YYYY	
	IMPLEMENTATION DATE:	MONTH 00, YYYY	
	<input type="checkbox"/> CONTROLLED COPY	<input type="checkbox"/> UNCONTROLLED COPY _____	

**TITLE : PROCESS – DEVELOPING – AQUEOUS SOLUTION INJECTIONS FOR HOSPITALS – COMPOUNDING PRACTICES**

Page 2 of 10

## RELATED LOGS & FORMS

RECORD	SPECIFICATION / DESCRIPTION

## RELATED STANDARD OPERATING PROCEDURES

SOP CODE	SOP TITLE

DISCLAIMER: Copyright© Medisca Pharmaceutique Inc. 2015-2020. Any reproduction, reprint or copy, in electronic or print version, is strictly prohibited without the expressed written consent of Medisca Pharmaceutique Inc. Medisca Network Inc takes no responsibility for the content of this document and shall not be held liable to any person or entity concerning claims, loss, or damage cause by, or alleged to be cause by, directly or indirectly, the use or misuse of the information contained in the suggested Standard Operating Procedures. Adjustments may be needed by end-user licensed pharmacist or other appropriately state licensed professional prior to use, to meet specific needs. Medisca Network Inc. shall not be liable for any adjustments made to the suggested Standard Operating Procedures. All suggested Standard Operating Procedures should be validated, approved and authorized for use by the end-user licensed pharmacist or other appropriately state licensed professional prior to use. In all cases, it is the responsibility of the licensed pharmacist or other appropriately state licensed professional to know the law and to act in accordance with federal and state law.

# Standard Operating Procedure

	SOP CODE:	USA – STRL – P4.1.2.0	REVISION NUMBER: 2 . 0 . 0
	ISSUE DATE:	MONTH 00, YYYY	
	IMPLEMENTATION DATE:	MONTH 00, YYYY	
	<input type="checkbox"/> CONTROLLED COPY	<input type="checkbox"/> UNCONTROLLED COPY _____	
<b>TITLE : PROCESS – DEVELOPING – AQUEOUS SOLUTION INJECTIONS FOR HOSPITALS – COMPOUNDING PRACTICES</b>			
Page 3 of 10			

## RESPONSIBILITIES

1. Designated Person oversees this SOP.
2. All compounding personnel must comply with this SOP.

## PURPOSE

1. To provide *products that are aqueous solutions for injection* to hospitals during the COVID-19 pandemic in accordance with FDA requirements.

## SCOPE

1. Applies to all compounding practices.
2. Applies to non-hazardous and hazardous sterile compounding.
3. Applies to the list of drugs used for hospitalized patients with COVID-19 maintained on the FDA's website and contains only one active ingredient.
  - a. <http://www.fda.gov/media/138279/download>

## DEFINITIONS

1. Not applicable.

## FREQUENCY

1. Comply with this SOP with each Work Order Filled.
2. Recommended to check the FDA website link to the list of permitted active ingredients under the provisions of this FDA policy.

	SOP CODE:	USA – STRL – P4.1.2.0	REVISION NUMBER: 2 . 0 . 0
	ISSUE DATE:	MONTH 00, YYYY	
	IMPLEMENTATION DATE:	MONTH 00, YYYY	
	<input type="checkbox"/> CONTROLLED COPY	<input type="checkbox"/> UNCONTROLLED COPY _____	
<b>TITLE : PROCESS – DEVELOPING – AQUEOUS SOLUTION INJECTIONS FOR HOSPITALS – COMPOUNDING PRACTICES</b>			
Page 4 of 10			

**SPECIAL CIRCUMSTANCE**

1. This SOP does not address *products that are aqueous solutions for injection* not listed in on the following FDA website link:

- a. <http://www.fda.gov/media/138279/download>

**PROCEDURE**

1. Before filling the Work Order...

1. Confirm the compounded drug product appears on the FDA website list of drugs used for hospitalized patients with COVID-19 and contains only one of the active ingredients listed.
2. Ensure the compounded drug is provided directly to the hospital and that...
  - a. The hospital is treating patients with COVID-19, and...
  - b. The hospital has made reasonable attempts to obtain, and has not been able to obtain:
    - i. Adequate supplies of an FDA-approved drug product containing the same active ingredient for the same route of administration, and...
    - ii. Adequate supplies of a product made by an outsourcing facility containing the same active ingredient for the same route of administration.

2. Before filling the Work Order...

1. Establish the beyond-use-date (BUD) for the prepared compounded product in accordance with the following rules and BUD table:
  - a. If the literature or other scientific information, including relevant commercially available product labeling for a similar drug (e.g., components, dosage form, route of administration, primary container-closure type) indicates that the drug product is not physicochemically stable for the duration of the BUD period listed in Table 1: Beyond-Use Dating, then...
    - i. The pharmacy must use a shorter BUD that is supported by the literature or other scientific information, and...
  - b. If the pharmacy is unable to obtain a sufficient supply of the personal protective equipment (PPE) in compliance with the *insanitary condition provision*<sup>1</sup> in the FD&C Act 11 (or PPE that is equivalent or better), then...
    - i. The pharmacy must apply BUDs of 24 hours for products stored at room temperature and 3 days for products stored refrigerated.

<sup>1</sup> <https://www.fda.gov/drugs/human-drug-compounding/regulatory-policy-information>

	SOP CODE:	USA – STRL – P4.1.2.0	REVISION NUMBER: 2 . 0 . 0
	ISSUE DATE:	MONTH 00, YYYY	
	IMPLEMENTATION DATE:	MONTH 00, YYYY	
	<input type="checkbox"/> CONTROLLED COPY	<input type="checkbox"/> UNCONTROLLED COPY _____	
<b>TITLE : PROCESS – DEVELOPING – AQUEOUS SOLUTION INJECTIONS FOR HOSPITALS – COMPOUNDING PRACTICES</b>			
Page 5 of 10			

- c. If the conditions of Procedural steps 2.1.a. and 2.1.b can be met, and the requirements of Table 1: Beyond-Use Dating can be met, then the beyond-use dating in Table 1: Beyond-Use Dating can be applied.

Table 1: Beyond-Use Dating		
Processing Conditions	Storage Conditions	
	Controlled Room Temperature (20° to 25°C)	Refrigerator (2° to 8°C)
<ul style="list-style-type: none"> <li>▪ Finished drug product is aseptically processed; and</li> <li>▪ A sterility test has not been completed before release</li> </ul>	4 days	6 days
<ul style="list-style-type: none"> <li>▪ Finished drug product is terminally sterilized;</li> <li>▪ A verified sterilization cycle that uses biological indicators is employed; and</li> <li>▪ A sterility test has not been completed before release</li> </ul>	10 days	12 days
<ul style="list-style-type: none"> <li>▪ Finished drug product is aseptically processed or terminally sterilized and has a completed, passing sterility test before release<sup>2</sup></li> </ul>	20 days Suggested with 'Passed' sterility test completed.	22 days Suggested with 'Passed' sterility test completed.

3. Before filling the Work Order...

- a. If the pharmacy and the hospital are not owned and controlled by the same entity, the pharmacy must...
- i. Mark the order with a notation indicating that the drug is provided to the hospital to treat patients during the COVID-19 public health emergency, and...
  - ii. Provide the hospital with a tracking document whereby the hospital can identify the patients to whom the drugs were administered.
  - iii. Request that the hospital provide, to the extent allowed by applicable laws, the records that identify the patients to whom the drugs were administered, and...
    - a. Document such request within one month of sending the compounded drug to the hospital.

<sup>2</sup> The default beyond use dates in this row include the time necessary to complete a sterility test, which may include rapid sterility test methods as well as sterility testing described under US Pharmacopeia (USP) General Chapter <71>.

	SOP CODE:	USA – STRL – P4.1.2.0	REVISION NUMBER: 2 . 0 . 0
	ISSUE DATE:	MONTH 00, YYYY	
	IMPLEMENTATION DATE:	MONTH 00, YYYY	
	<input type="checkbox"/> CONTROLLED COPY	<input type="checkbox"/> UNCONTROLLED COPY _____	
<b>TITLE : PROCESS – DEVELOPING – AQUEOUS SOLUTION INJECTIONS FOR HOSPITALS – COMPOUNDING PRACTICES</b>			
Page 6 of 10			

4. Before filling the Work Order...

- a. The State-licensed pharmacy must notify the following State authorities, and the State authorities must inform the pharmacy that they do not object to the pharmacy providing the drug product to the hospital without first obtaining a patient-specific prescription.
  - i. The State authorities include:
    - a. The State authority that regulates pharmacy compounding in the State where the pharmacy is located, and...
    - b. If different, the State authority that regulates pharmacy compounding in the State where the hospital is located.
  - b. The pharmacy acquires State required local requirements.
  - c. Products allowed to be compounded, and that are prepared, as aqueous solutions for injection must be identified at...
    - i. <http://www.fda.gov/media/138279/download>
  - d. Consider maintaining a record of when the FDA approved the use of a given active ingredient, and then when it was no longer approved under this provision.
    - i. Suggested maintaining a record using the table below.
    - ii. Maintain these records fully documented for your permanent record.

Table 2: List of Drugs Used for Hospitalized Patients with COVID-19		
Products that are aqueous solutions for injection:	Date FDA approved...	Date no longer FDA approved...

- e. Consider storage and approved labelling requirements as per USP standards for comparable FDA-approved products.
  - i. Note: Certain syringes and rubber stoppers have been associated with loss of potency in certain products.<sup>3</sup>

<sup>3</sup> <https://www.fda.gov/drugs/drug-safety-and-availability/fda-notifies-health-care-professionals-becton-dickinson-replaced-problematic-rubber-stoppers-its>.

	SOP CODE:	USA – STRL – P4.1.2.0	REVISION NUMBER: 2 . 0 . 0
	ISSUE DATE:	MONTH 00, YYYY	
	IMPLEMENTATION DATE:	MONTH 00, YYYY	
	<input type="checkbox"/> CONTROLLED COPY	<input type="checkbox"/> UNCONTROLLED COPY _____	
<b>TITLE : PROCESS – DEVELOPING – AQUEOUS SOLUTION INJECTIONS FOR HOSPITALS – COMPOUNDING PRACTICES</b>			
Page 7 of 10			

5. Ensure Adverse Event reporting associated with products prepared under this provision are reported as soon as possible, and no later than 15 days after the receipt of such information.

a. The FDA MedWatch Reporting Program applies.

<https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program>

<https://www.accessdata.fda.gov/scripts/medwatch/index.cfm>

b. The pharmacy should complete and submit...

i. Form FDA 3500 for Healthcare Professionals

<https://www.fda.gov/media/76299/download>

c. Submit the Form FDA 3500, via fax, to 1-800-FDA-0178.

d. At a minimum, the following information must be submitted:

i. Compounder name and contact information

ii. Patient information (if available).

iii. Product information (i.e., ingredients, strength, dosage form, lot number, and beyond-use date).

iv. Description of the Adverse Event.

# Standard Operating Procedure

	SOP CODE:	USA – STRL – P4.1.2.0	REVISION NUMBER: 2 . 0 . 0
	ISSUE DATE:	MONTH 00, YYYY	
	IMPLEMENTATION DATE:	MONTH 00, YYYY	
	<input type="checkbox"/> CONTROLLED COPY	<input type="checkbox"/> UNCONTROLLED COPY _____	
<b>TITLE : PROCESS – DEVELOPING – AQUEOUS SOLUTION INJECTIONS FOR HOSPITALS – COMPOUNDING PRACTICES</b>			
Page 8 of 10			

## VERIFICATION

1. Confirm updated versions to this FDA GFI document on a regular basis and record the date the Work Order is filled.
2. Confirm modifications to the list of drugs used for hospitalized patients with COVID-19 maintained on the FDA's website and contains only one active ingredient.
  - b. <http://www.fda.gov/media/138279/download>

## CORRECTIVE ACTIONS

1. Modify the 'Products that are aqueous solutions for injection' list in the SOP with each Work Order filled.

## PREVENTIVE ACTIONS

1. Not applicable.



# Standard Operating Procedure

	SOP CODE:	USA – STRL – P4.1.2.0	REVISION NUMBER: 2 . 0 . 0
	ISSUE DATE:	MONTH 00, YYYY	
	IMPLEMENTATION DATE:	MONTH 00, YYYY	
	<input type="checkbox"/> CONTROLLED COPY	<input type="checkbox"/> UNCONTROLLED COPY _____	

**TITLE : PROCESS – DEVELOPING – AQUEOUS SOLUTION INJECTIONS FOR HOSPITALS – COMPOUNDING PRACTICES**

Page 9 of 10

## TECHNOLOGICAL RESOURCES

EQUIPMENT	MANUFACTURER	MAKE	MODEL	SERIAL NUMBER	ID CODE

## EDUCATIONAL AND SERVICE RESOURCES

AVAILABLE OFFERINGS	

## SPECIFICATION DOCUMENTS

DOCUMENT NUMBER	DOCUMENT NAME	SOURCE	DESCRIPTION

DISCLAIMER: Copyright© Medisca Pharmaceutique Inc. 2015-2020. Any reproduction, reprint or copy, in electronic or print version, is strictly prohibited without the expressed written consent of Medisca Pharmaceutique Inc. Medisca Network Inc takes no responsibility for the content of this document and shall not be held liable to any person or entity concerning claims, loss, or damage cause by, or alleged to be cause by, directly or indirectly, the use or misuse of the information contained in the suggested Standard Operating Procedures. Adjustments may be needed by end-user licensed pharmacist or other appropriately state licensed professional prior to use, to meet specific needs. Medisca Network Inc. shall not be liable for any adjustments made to the suggested Standard Operating Procedures. All suggested Standard Operating Procedures should be validated, approved and authorized for use by the end-user licensed pharmacist or other appropriately state licensed professional prior to use. In all cases, it is the responsibility of the licensed pharmacist or other appropriately state licensed professional to know the law and to act in accordance with federal and state law.

# Standard Operating Procedure

	SOP CODE:	USA – STRL – P4.1.2.0	REVISION NUMBER: 2 . 0 . 0
	ISSUE DATE:	MONTH 00, YYYY	
	IMPLEMENTATION DATE:	MONTH 00, YYYY	
	<input type="checkbox"/> CONTROLLED COPY	<input type="checkbox"/> UNCONTROLLED COPY _____	

**TITLE : PROCESS – DEVELOPING – AQUEOUS SOLUTION INJECTIONS FOR HOSPITALS – COMPOUNDING PRACTICES**

Page 10 of 10

## REVISION HISTORY

REVISION NUMBER	IMPLEMENTATION DATE	TERMINATION DATE	SUMMARY OF CHANGE TO CURRENT VERSION

## REGULATORY COMPLIANCE GUIDELINES AND STANDARDS OF PRACTICE

REFERENCE SOURCE	REFERENCE CODE	REFERENCE DATE	SECTION CODE	SECTION DESCRIPTION
FDA Guide of Industry Document		April 2020  Updated May 21, 2020		Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency <sup>4</sup> (Revised)

<sup>4</sup> <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/temporary-policy-compounding-certain-drugs-hospitalized-patients-pharmacy-compounders-not-registered>